Michael Adler, PhD, is currently Director Drug Product Design at ten23 health in Basel (Switzerland). He has over 20 years of industry experience at different pharmaceutical companies, including Abbott (now AbbVie), Roche, Lonza and ten23 health. He has vast experience in early and late-stage formulation and drug product manufacturing process development for both liquid and lyophilised dosage forms. His area of expertise also covers process transfer, process characterisation and validation and commercial support for biological drug products, including combination products and small-molecule parenterals. Dr Adler has driven development of monoclonal antibodies and novel antibody-derived formats, fusion proteins, PEGylated proteins, synthetic peptides and oligonucleotides for intravenous, subcutaneous, intravitreal and intrathecal delivery. He has extensive knowledge with regards to regulatory registration activities, as well as health authority interactions for the US, Europe and elsewhere. Dr Adler studied Pharmacy at the University of Heidelberg (Germany) and holds a PhD in Pharmaceutical Technology from the University of Erlangen-Nürnberg (Germany).